In silico analysis of hexokinase- I and II as potential drug targets in cancer

Sudhir Ranjan Bhoi, Nihar Ranjan Panda, Rakesh M. Rawal, Mukesh Kumar Raval

Abstract


Objective: Hexokinases in the glycolytic pathway exhibit enhanced catalytic activity in malignant cells. In order to control cancer cell growth, the activity of the enzyme needs to be dampened. In the present study, an in silico approach is made to find potential phytochemical inhibitors of hexokinase I and II.

Methods: ArgusLab software is used to study the binding affinity of ligands in the active site of the protein. Computation of drug-likeness and oral toxicity is done using the online tools Molsoft and ProTox respectively.

Results: A flavonoid, 1, 2-dihydrobis (de-O-methyl)-curcumin, shows better binding affinity to the substrate as well as cofactor binding sites of both hexokinase I and II. The LD50 value (median lethal dose) is 2000 and the toxicity class is 4. There is no tox related fragments found in this structure and no possible binding to any toxicity targets.

Conclusions: 1, 2-dihydrobis (de-O-methyl)-curcumin is the inhibitor of choice, a lead molecule against targets: hexokinase I and II. The lead molecule may be the future drug for cancer treatment.

Keywords


Hexokinase-I and II, Cancer, 1, 2-dihydrobis (de-O-methyl)-curcumin, drug-likeness, toxicity, Molsoft, ProTox.

Full Text:

PDF HTML XML

References


Krasnov GS, Dmitriev AA, Sadtritdinova AF, Fedorova MS, Snezhkina AV, Melnikova NV, et al. Evaluation of Gene Expression of Hexokinases in Colorectal Cancer with the Use of Bioinformatics Methods. 2015;60(6):1050-6.

Bustamante E, Pedersen PL. High aerobic glycolysis of rat hepatoma cells in culture: Role of mitochondrial hexokinase. Proc Natl Acad Sci USA. 1977;74:3735–9.

Arora KK, Fanciulli M, Pedersen PL. Glucose phosphorylation in tumor cells. Cloning, sequencing, and overexpression in active form of a full length cDNA encoding a mitochondrial bindable form of hexokinase. J Biol Chem. 1990;265:6481–8.

Rempel A, Mathupala SP, Griffin CA, Hawkins AL, Pedersen PL. Glucose catabolism in cancer cells: Amplification of the gene encoding type II hexokinase. Cancer Res. 1996;56:2468–71.

Farnsworth NR. Ethnobotany and the Search for New Drugs, Wiley Willett WC. Diet and health: what should we eat. Science. 1994;264(5158):532–7.

Duraipandiyan V, Ayyanar M, Ignacimuthu S. Antimicrobial activity of some ethnomedicinal plants used by Paliyar tribe from Tamil Nadu, India. BMC Comp Alter Med. 2006;6:35-41.

Bhanot A, Sharma R, Noolvi MN. Natural sources as potential anti-cancer agents: A review. International Journal of Phytomedicine. 2011;3:09-26.

Prema R, Sekar SD, Chandra Sekhar KB. Review On: Herbs As Anticancer Agents. Int J Pharma & Ind Res. 2011;1:105.

Mangal M, Sagar P, Singh H, Raghava GPS, Agarwal SM. NPACT: Naturally Occurring Plant-based Anti-cancer Compound-Activity-Target database. Nucleic Acids Research. 2013;41:D1124 - 9.

Drwal MN, Banerjee P, Dunkel M, Wettig MR, Preissner R. ProTox: A web server for the in silico prediction of rodent oral toxicity. Nucleic Acids Res (Web server issue 2014).

Schmidt U, Struck S, Gruening B, Hossbach J, Jaeger IS, Parol R, et al. SuperToxic: a comprehensive database of toxic compounds. Nucleic Acids Res. 2009;37:D295-9.

Ali MS, Tezuka Y, Awale S, Banskota AH, Kadota S. Six new diarylheptanoids from the seeds of Alpinia blepharocalyx. J Nat Prod. 2001;64(3):289-93.

Kadota S, Tezuka Y, Prasain JK, Ali MS, Banskota AH. Novel diarylheptanoids of Alpinia blepharocalyx. Curr Top Med Chem. 2003;3(2):203-25.

Bustamante E, Morris HP, Pedersen PL. Energy metabolism of tumor cells. J Biol Chem. 1981;256:8699–704.

Nakashima RA, Paggi MG, Scott LJ, Pedersen PL. Purification and characterization of a bindable form of mitochondrial bound Hexokinase from highly glycolytic AS-30D hepatoma cell line. Cancer Res. 1988;48:913–9

Mathupala SP, Rempel A, Pedersen PL. Glucose catabolism in cancer cells: Isolation, sequence and activity of the promoter for Type II Hexokinase. J Biol Chem. 1995;270:6918–25.

Kang H-M, Son K-H, Yang DC, Han D-C, Kim JH, Baek N-I, et al. Inhibitory Activity of Diarylheptanoids on Farnesyl Protein Transferase. Natural Product Research. 2004;18(4):295–9.


Refbacks

  • There are currently no refbacks.




Copyright (c) 2016 Pharmaceutical and Biological Evaluations

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.



Creative Commons License

 

© Copyright 2018 - Pharmaceutical and Biological Evaluations